TNF and inflammatory bowel disease: In IBD, updated guidelines from the American College of Gastroenterology (ACG) highlight the role of biologics such as TNF inhibitors, vedolizumab, and ustekinumab in achieving and maintaining remission, with recommendations for regular monitoring of response and adverse effects [1].